Log in to search using one of your social media accounts:


With latest drug trial, Sage catapults into top 5 most valuable Mass. biotechs

Sage Therapeutics saw its market cap jump more than $2.5 billion on Thursday after announcing that one of its depression drugs had aced a mid-stage trial, vaulting the Cambridge-based company into the state ’s top five most valuable biotechs. Sage (Nasdaq: SAGE) announced that the drug, called SAGE-217, had helped to reduce symptoms of major depressive disorder in the Phase 2 study. The 187-employee company now hopes to move the drug into a Phase 3 trial before potentially seeking approval from…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

More News: Biotechnology | Depression | Health Management | Pharmaceuticals | Study